X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CORT118335 (miricorilant) is a potent, orally active non-steroidal glucocorticoid receptor (GR) antagonist that is being developed for the treatment of Non-Alcoholic Steatohepatitis.
Lead Product(s): Miricorilant
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CORT118335
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
CORT118335 (miricorilant) is a potent, orally active non-steroidal glucocorticoid receptor (GR) antagonist that is being developed for the treatment of Non-Alcoholic Steatohepatitis.
Lead Product(s): Miricorilant
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CORT118335
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
CORT118335 (miricorilant) is a potent, orally active non-steroidal glucocorticoid receptor (GR) antagonist that is being developed by Corcept Therapeutics.
Lead Product(s): Miricorilant
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CORT118335
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Subjects who received miricorilant, selective cortisol modulator gained significantly less weight than those who received placebo, as a potential treatment for patients with weight gain caused by antipsychotic medication use.
Lead Product(s): Miricorilant
Therapeutic Area: Nutrition and Weight Loss Product Name: CORT118335
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
Corcept Therapeutics announced interim findings from the Phase 2 trial of its selective cortisol modulator miricorilant in patients with presumed NASH. First trial of the company to evaluate miricorilant as a treatment for patients with liver disease.
Lead Product(s): Miricorilant
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CORT118335
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
GRATITUDE I, Corcept’s first Phase 2 trial of miricorilant in APIWG, continues to enroll patients with schizophrenia and recent weight gain.
Lead Product(s): Miricorilant
Therapeutic Area: Nutrition and Weight Loss Product Name: CORT118335
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
